Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 210040, China.
Cancer Lett. 2012 Dec 29;326(1):17-22. doi: 10.1016/j.canlet.2012.07.024. Epub 2012 Jul 25.
Early metastases of hepatocellular carcinoma (HCC) may be detected by the isolation of circulating tumor cells (CTCs) in the bloodstream. During the course of therapeutic attempts, monitoring CTC changes in patients with HCC is helpful for the efficacy assessment. Nevertheless, the markers used for the detection, such as α-feto protein, asialoglycoprotein receptor or epithelial cell adhesion molecule, CD133 or CD90, are not specific for HCC CTCs. In spite of these limitations, a timely determination of the existence of CTCs will be beneficial for the monitoring of distant metastases, the evaluation of therapeutic attempts, and the prediction of prognosis.
早期肝细胞癌 (HCC) 的转移可能通过在血液中分离循环肿瘤细胞 (CTC) 来检测。在治疗尝试过程中，监测 HCC 患者的 CTC 变化有助于评估疗效。然而，用于检测的标志物，如甲胎蛋白、去唾液酸糖蛋白受体或上皮细胞黏附分子、CD133 或 CD90 等，并不特异于 HCC CTC。尽管存在这些局限性，但及时确定 CTC 的存在将有助于监测远处转移、评估治疗尝试和预测预后。
